Cargando…

SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis

Background: Empagliflozin is a sodium glucose co-transporter 2 (SGLT-2) inhibitor that works in the proximal renal tubules reducing resorption of glucose and increasing urinary glucose excretion. It effectively lowers glycated hemoglobin (HbA1C) values and reduces risks of adverse cardiovascular eve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Mathew, Tran, Ly, White, Christopher, Deppe, John, Davidson, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552746/ http://dx.doi.org/10.1210/js.2019-SUN-LB030

Ejemplares similares

SAT-LB118 Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Arao, Kevin A, et al.
Publicado: (2020)

MON-LB119 Euglycemic Diabetic Ketoacidosis in a Patient on Canagliflozin Presenting With Hypoglycemia
por: Inkollu, Sindhura, et al.
Publicado: (2020)

SUN-178 A Not So "Sweet" DKA: A Case of Euglycemic Diabetic Ketoacidosis Caused by Dapagliflozin/Liraglutide Combination
por: Sideri Gugger, Aristea, et al.
Publicado: (2019)

SUN-183 Prolonged Glycosuria after Canagliflozin Discontinuation in a Patient with Euglycemic Diabetic Ketoacidosis
por: Dai, Yufei, et al.
Publicado: (2019)

ODP192 Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad
por: Nievera, Karl Homer, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

MON-LB124 Euglycemic Diabetic Ketoacidosis on Initiation of Ertugliflozin in a Patient With Type 2 Diabetes Mellitus Precipitated by a Ketogenic Diet
por: Richstein, Ryan, et al.
Publicado: (2020)

SUN-LB025 Superior Mesenteric Artery Thrombosis: An Uncommon Complication of Diabetic Ketoacidosis
por: Saini, Khushpreet Kaur, et al.
Publicado: (2019)

A Case of Euglycemic Diabetic Ketoacidosis Following Canagliflozin Therapy
por: Tuna, Kubra M, et al.
Publicado: (2021)

SUN-LB036 Diabetic Ketoacidosis: A Rare Side Effect of Nivolumab Induced Insulin Dependent Diabetes Mellitus
por: Abid, Haisam, et al.
Publicado: (2019)

SUN-700 Fournier’s Gangrene and Diabetic Ketoacidosis Caused by Canagliflozin
por: Stamatiades, George Alexiades, et al.
Publicado: (2020)

SUN-176 Euglycemic Diabetic Ketoacidosis withSGLT2 Inhibitor Presenting as Chest Pain in a Patient with Coronary Artery Disease on a Ketogenic Diet
por: Dorcely, Brenda, et al.
Publicado: (2019)

SUN-673 Development of Euglycemic Diabetic Ketoacidosis in a Patient with Well-Controlled Type 2 Diabetes Mellitus on a Sodium-Glucose Transporter 2 Inhibitor
por: Narang, Disha K, et al.
Publicado: (2020)

MON-127 Euglycemic Diabetic Ketoacidosis: A Rare Complication of a Common Disease
por: Kazi, Fatima, et al.
Publicado: (2019)

SUN-LB029 A Case of Gestational Diabetes with Diabetic Ketoacidosis, Insulin Injection Site Reaction and Anti Insulin Antibodies in Pregnancy
por: Hakimian, Stephanie, et al.
Publicado: (2019)

MON-LB030 Muscle Mitochondrial Oxidative Phosphorylation Capacity and Whole Body Glucose Metabolism in Friedreich's Ataxia
por: Nguyen, Sara, et al.
Publicado: (2019)

MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis
por: Chhabra, Sarah, et al.
Publicado: (2020)

A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 Inhibitors
por: Marenych, Nadiia, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet
por: Hester, Joi C, et al.
Publicado: (2021)

SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 Inhibitors and Keto-Diet
por: Castellanos-Diaz, Jessica, et al.
Publicado: (2020)

SUN-LB028 Diabetic Truncal Radiculopathy: An Underrecognized Cause of Thoracic and Abdominal Pain
por: Panday, Deepika, et al.
Publicado: (2019)

MON-LB123 Diagnosis and Management of Euglycemic DKA in the Setting of SGLT2 Inhibitor Use and Prostate Abscess
por: Rameshkumar, Naveen Sundar
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis Post Bariatric Surgery in Type II DM in the Setting of SGLT2-Inhibitor Use
por: Alfares, Khalid, et al.
Publicado: (2021)

SUN-177 House Of Carbs: The Path To Euglycemic Dka In Patients With Diabetes On Sglt2 Inhibitors
por: Islam, Julie, et al.
Publicado: (2019)

MON-LB127 Pulmonary Embolism in the Setting of Diabetic Ketoacidosis. an Under-Recognized Complication
por: Ahmed, Adeel Jabran, et al.
Publicado: (2020)

Patient-Specific Risk Factors and Clinical Correlates of Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Co-Transporter-2 Inhibitors
por: Somagutta, Manoj Reddy, et al.
Publicado: (2021)

SUN-LB034 A Rare Cause of Hyperinsulinemic Hypoglycemia in Adulthood: A Case Report and Review of the Literature
por: Greyling, Christeman, et al.
Publicado: (2019)

SAT-LB030 Efficacy of Combined Therapy with Metformin and Sitagliptin in Patients with Type 2 Diabetes Who Did Not Reach Target Levels of Glycated Hemoglobin on Metformin Monotherapy
por: Klitsunova, Yuliia, et al.
Publicado: (2019)

MON-652 The Prevalence and Clinical Characteristics of Adult Patients Presenting with Sodium-Glucose Co-Transporter-2 Inhibitor Associated Euglycemic Diabetic Ketoacidosis
por: Clark, Alexa, et al.
Publicado: (2020)

SUN-LB026 Do CFTR Modulators Treat Cystic Fibrosis-Related Diabetes?
por: Mehfooz, Ayesha, et al.
Publicado: (2019)

MON-LB126 A Benign and Favorable Diagnosis: Glycogen Hepatopathy Causing Transient Transaminitis During Diabetic Ketoacidosis in Type 1 Diabetes Mellitus
por: Yau, Alice, et al.
Publicado: (2020)

SAT-LB119 Diabetic Ketoacidosis With PUMP Failure: Analysis of the 2006-2016 U.S. Kid Inpatient Database
por: Everett, Estelle, et al.
Publicado: (2020)

SUN-LB124 Novel Elisa Assays Demonstrate Specificity of Islet and Intestinal Processing of Proglucagon
por: D’Alessio, David A, et al.
Publicado: (2020)

SAT-LB031 Empagliflozin as an Add-On Medication to Subjects Uncontrolled on DPP4 Inhibitors and Metformin: Real World Data Supporting the Use of Empagliflozin as a Rational Second Add-On in Indian Type 2 Diabetic Patients
por: MS, ANEESH
Publicado: (2019)

THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)

SUN-167 Quetiapine-Induced Hypertriglyceridemia and Hyperglycemia Presenting as Simultaneous Diabetic Ketoacidosis and Acute Pancreatitis
por: Gandhi, Shriya, et al.
Publicado: (2019)

SUN-174 Severe Insulin Resistance and Diabetic Ketoacidosis after Brentuximab Vendotin and Cyclosporin Treatment
por: Lee, Hyunju, et al.
Publicado: (2019)

Euglycemic DKA Associated With SGLT2 Inhibitors
por: TakallooBakhtiari, Asieh, et al.
Publicado: (2021)

SUN-173 Nivolumab-Induced Fulminant Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Patient with Melanoma
por: Parikh, Sahil, et al.
Publicado: (2019)

SUN-LB119 Role of HNF4a Isoforms in the Carbohydrate/Lipid Switch in the Liver and Responsiveness to AMPK
por: Radi, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ju81s42sl1g1rnv3fl8dc824pt